CeNeS PH Plc

[Day-to-day]

This is an interesting company that could be going places.. I hold shares in the company but am in the red at this time..

Upbeat news from CeNeS. In addition to the clear nausea and vomiting reductions of over 25% announced last week, secondary data reveals that patients receiving M6G required over 20% less anti-emetic medication over the 0-24 hour period than those in the morphine group. This shows that not only does M6G induce significantly less nausea and vomiting than morphine, but also that the post-operative anti-emetic treatment required is considerably reduced.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assistance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine. In a nutshell these results are first class. The S.P. has move up over the last few days not a lot but it moved.

CeNeS preliminary results will be out on Wednesday 28th March.. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics.

 

[Day-to-day]

CeNeS is an emergin pharmaceutical company specialising in CNS drugs. It has four programmes in various stages of development, the most advanced being a morphine metabolite, M6G. Other projects include an NMDA antagonist in Phase II trials for neuropathic pain relief, a short-acting sedative for day-surgery, and a COMT programme for Parkinson’s disease.

The successful outcome should lead to a licensing agreement with a specialty pharmaceutical partner for M6G being struck later in 2007. However, there is also a wealth of potentially positive new flow set to arise from the remaining programmes during the year. All three products - CNS5156 for neuropathic pain, CNS7056B a sedative for day-case surgery and the COMT inhibitor for Parkinson’s disease - could generate material news flow during the year.

Valuation suggested that M6G was worth 7.9p a share but, following this successful trial, now rises to 10.4p. This coupled with 4.2p for the remainder of the development portfolio, means that, after adjusting for the net cash position, R&D expenditure and G&A costs, now value CeSeN shares at 14.2p a share - up from 11.7p a share previously.

On the back of this.. Barclays Plc now has a total holding in CeNeS of 13.97%

 

[Day-to-day]

CeNeS M6G. Since the announcement of the successful data significant interest has been expressed by Pharma companies in reviewing the large M6G data package that CeNeS has assembled. CeNeS is on record as saying that the company is confident that agreements can be finalised with partner(s) based on the existing set of clinical trial data. Concluding these deals will generate short term income and recurring revenue streams from a successful product launch in the future.

 

[Day-to-day]

CeNeS key factor Appoints Rodman & Renshaw to assist in partnering of M6G the US based healthcare specialist investment bank, to assist in the partnering of morphine-6-glucuronide ("M6G"), its novel drug for the treatment of post-operative pain. This is indeed first class news, proving that the company is now ready to take on a partner to market M6G

Leo Slepak Managing Director (M&A and Licensing Group) of Rodman & Renshaw, is on record as saying that M6G should translate into a commercially valuable drug.

 

[pssonice]

BUY CEN.L @ 600 s520 t650 today

great pick. well done

 

[pssonice]

BUY CQG.STUTTGART @10c nostop (german market)

Cenes Pharmaceuticals Plc